Immunovia has announced that Thomas King, MD, PhD, Medical Director of Immunovia, Inc. was awarded the Presidential Poster Award at the American College of Gastroenterology (ACG) Annual Scientific Meeting for the blind validation results for the IMMray PanCan-d test.
The abstract reports the results of Immunovia, Inc.’s blind validation study, demonstrating that the IMMray PanCan-d test can identify stage I & II pancreatic ductal adenocarcinoma (PDAC) with 89% sensitivity and 99% specificity, describes the company in a press release.
“It is very positive that Immunovia has received the ACG Presidential Poster Award. ACG is a recognized leader in educating gastrointestinal professionals and this shows how important our IMMray™ PanCan-d test is to the medical community, and the contribution it can make to the early detection of pancreatic cancer. The ACG Presidential Poster Award is also a significant step in building our dossiers that will contribute to our discussions with payers to achieve reimbursement for the test,” says Patrik Dahlen, CEO of Immunovia.
Read more: Interview Patrik Dahlen, CEO, Immunovia
Photo of Thomas King, Medical Director, Immunovia